BILLERICA, Mass., Feb. 14, 2018 /PRNewswire/ -- Bruker is
pleased to announce that AOAC International has approved the
MALDI Biotyper solution for two new Official Methods of
Analysis (OMA) for the confirmation and identification of
pathogenic and non-pathogenic bacteria. The two methods
include some of the most common food pathogens, including
Salmonella spp (spp means all species of the genus
Salmonella), Cronobacter spp, Listeria spp and
Listeria monocytogenes, as well as the identification of
other Gram-negative and Gram-positive bacteria. Confirmation
and identification can be performed directly from several selective
culture media that are widely used in food microbiology, or from
any non-selective culture plates.
The added value of using the MALDI Biotyper as a very
fast and cost-effective microbial confirmation and identification
solution is now also broadly available for food safety authorities,
for food industries, and other food and feed testing facilities.
This can improve efficiency in food testing laboratories and
accelerate the turn-around time for food producers until critical
production steps are monitored, and lots can be released.
Validation studies have proven the performance of the MALDI
Biotyper for the direct confirmation and identification of
bacteria from the selective media recommended by the FDA, ISO and
USDA, as well as from several chromogenic media, and from any
non-selective culture media. The approved benchtop MALDI
Biotyper system is also available as an MBT smart
version with an even faster, proprietary smartbeam™ laser
that further accelerates the speed of analysis and decreases
time-to-result.
The MALDI Biotyper Subtyping Module enables a high
confidence differentiation of the Listeria species.
The MALDI Biotyper workflow can be supported with the
MBT Pilot™ for optically guided sample preparation on the
MBT target plates, and with the MBT Galaxy™ for
automated matrix deposition during the sample preparation.
Both workflow tools further improve the productivity and
workflow standardization. New disposable MBT Biotargets
96 plates based on Bruker´s proprietary AnchorChip™
technology can be used for optimal performance.
Erin Crowley, the Chief
Scientific Officer at Q Laboratories in Cincinnati, Ohio, commented: "Q
Laboratories was grateful for the opportunity to serve as the
Expert Laboratory on these two OMA validation studies. The
success of these projects was supported by the easy workflow of the
MALDI Biotyper. We have implemented the MALDI
Biotyper in our facilities since 18 months already. It is
truly an innovation and its OMA approval is a significant step to
provide our customers with rapid and accurate identification and
confirmatory options needed to make critical decisions."
Q Laboratories Inc. is an ISO/IEC 17025 accredited laboratory
providing comprehensive microbiological, analytical chemistry and
R&D laboratory services to companies around the world. In
business since 1966, Q Laboratories serves the food,
pharmaceutical, cosmetic, dietary supplement and personal care
product industries and is the first Expert Laboratory in
North America to be recognized by
the three major certification bodies AFNOR, AOAC International and
MicroVAL.
Dr. Daniele Sohier, Business
Development Manager for Industrial Microbiology at Bruker
Daltonics, added: "Working in collaboration with AOAC International
and Q Laboratories was a real pleasure and very efficient. We
were able to get these two OMA claims in only 6 months,
corroborating the reliability and robustness of the MALDI
Biotyper for fast and accurate confirmation of many foodborne
pathogens and for the identification of other bacteria. The
MALDI Biotyper is broadly used in clinical microbiology
already. With the AOAC International approvals for two OMAs,
we now also have access to regulated food microbiology markets,
which represents a further significant market expansion for the
MALDI Biotyper."
About the Bruker MALDI Biotyper (MBT) Platform
The MALDI Biotyper family of systems enables molecular
identification of microorganisms like bacteria, yeasts and
fungi. Classification and identification of microorganisms is
achieved reliably and quickly using proteomic fingerprinting by
high-throughput MALDI-TOF mass spectrometry. The MALDI
Biotyper uses a molecular approach based on specific proteomic
fingerprints from bacterial strains. Many published studies
have highlighted the greater accuracy and lower cost offered, as
well as typically much faster time-to-result (TTR).
Applications of various MALDI Biotyper solutions include
clinical routine microbial identification, environmental and
pharmaceutical analysis, food safety and quality, taxonomical
research, as well as marine microbiology. In many European
and international laboratories the MALDI Biotyper has
replaced classical biochemical testing for bacterial identification
in the past few years due to the accuracy, speed, extensive species
coverage, ease of use and cost effectiveness of the system.
Traditional biochemical techniques detect different metabolic
properties of microorganisms, can take many hours or even days for
completion, and they often lack specificity.
The robust MALDI Biotyper requires minimal sample
preparation and offers low consumables cost. The products of
the MALDI Biotyper family are available in a
research-use-only (RUO) version, as the U.S. FDA-cleared MALDI
Biotyper CA System, or in an IVD-CE version according to EU
directive EC/98/79. The MALDI Biotyper also has
medical device registrations in numerous other countries. RUO
versions of the MALDI Biotyper allow selected, high-value
antimicrobial resistance tests.
About Bruker Corporation (NASDAQ: BRKR)
For more than 55 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific instruments and high-value analytical and diagnostic
solutions enable scientists to explore life and materials at
molecular, cellular and microscopic levels. In close
cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular
research, in applied and pharma applications, in microscopy,
nano-analysis and industrial applications, as well as in cell
biology, preclinical imaging, clinical phenomics and proteomics
research, clinical microbiology and molecular pathology
research. Please visit: www.bruker.com
Investor
Contact:
Miroslava
Minkova
Bruker Head of Investor
Relations
T: +1 (978) 663–3660, ext.
1479
E: miroslava.minkova@bruker.com
Contact for Media and Customers:
Dr. Daniele Sohier
Bruker Daltonics Division
Tel: +49-173-356-7697
E: daniele.sohier@bruker.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/the-bruker-maldi-biotyper-solution-receives-aoac-international-approvals-for-two-official-methods-of-analysis-oma-in-food-microbiology-300598506.html
SOURCE Bruker Corporation